EUCTR2015-002408-97-ES
Active, not recruiting
Phase 1
Comparative Study, intraindividual to evaluate efficacy and safety of the treatment of actinic keratosis with photodinamic therapy between methyl aminolevulinate cream and aminolevulinic acid nanosome gel
Dr. Carlos Serra0 sitesOctober 5, 2015
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Actinic Keratosis
- Sponsor
- Dr. Carlos Serra
- Status
- Active, not recruiting
- Last Updated
- 9 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Eligible patients may present at least 5 QA in two symmetrical areas of the face or the scalp. Can not be significant differences in the number QAs between the two treatment areas.
- •1\. Patients older than 18 years and able to give informed consent.
- •2\. Patients must have at least 5 QA in two symmetrical areas of the face or the scalp.
- •3\. Patients must no use solar protection creams or other creams (retinoic, hydroxiacids, emollients, topic antibiotics) on the treatment area during the study time.
- •4\. Patients must agree to postpone the treatment of the other actinic keratosis lesions close to the treatment area.
- •5\. Patients must agree going to the scheduled visits where they have to complete a form with epidemiology aspects, baseline characteristics, and satisfaction with the treatment received and taking pictures of the treatment area on each visit.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 50
Exclusion Criteria
- •Perioral and periocular areas of the face will be discarded as treatment zones. Patients with previous treatment with photodynamic therapy in the face or the scalp for any lesion. Patients with previous treatment for actinic keratosis in the previous 3 months, patients with inmunosuppression treatment, and patients with inherited diseases which can predispose to cutaneous cancer (Gorlin syndrome, xeroderma pigmentosum.
- •1\. Patients who have clinical evidence of inmunosuppression, unstable cardiovascular diseases, haematological, hepatic, neurological, renal or endocrine diseases. Patients with stables medical conditions like high blood pressure. diabetes mellitus, hypercholesterolemia, etc. can be included in the study.
- •2\. Patients who suffer form any dermatological disease in the treatment zone or around it.
- •3\. Patients who have received previous treatment with photodynamic therapy in the selected areas.
- •4\. Patients who have alcohol or drug dependency.
- •5\. Being currently participating in other studies
- •6\. Patients who have received any of the following treatments in less time than indicated:
- •\- Systemic chemotherapy, in the last 6 months
- •\- Systemics retinoids, interferon, inmunomodulators or inmunosuppressors, cytotoxic agents, systemic corticoids, in the last month
- •\- PUVA, UVB, ablative lasers, dermabrasion, chemical peelings, in the last 6 months
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
A study to compare the individual and combined effect of nerve flossing technique and intermittent lumbar traction on Pain and disability in lumbar radiculopathy patients.CTRI/2019/02/017840Government physiotherapy collegeJamnagar
Not yet recruiting
Phase 2
Management of Polycystic Ovarian Syndrome by AyurvedaHealth Condition 1: E282- Polycystic ovarian syndromeCTRI/2022/08/045045Principal RGGPG Ayurvedic College and Hospital Paprola
Not yet recruiting
Not Applicable
a clinical study to evaluate the comparative effect of shatavari and ashwagandha on shukra kshayaCTRI/2021/09/036415Government ayurvedic college patiala
Not yet recruiting
Phase 2
A Comparative Clinical study to see the effect of some Ayurvedic formulation in patients of itching in vulvaHealth Condition 1: N768- Other specified inflammation of vagina and vulvaCTRI/2021/03/032120State Ayurvedic College and Hospital lucknow
Not yet recruiting
Not Applicable
Comparative Effect of Basti therapy of Ayurveda in chronic kidney disease treatmentHealth Condition 1: N183- Chronic kidney disease, stage 3 (moderate)CTRI/2024/07/070318All India Institute of Ayurveda (AIIA)